导航阿尔茨海默病生物标志物景观:基于流体的诊断的全面分析
Elsa El Abiad1, Ali Al-Kuwari1, Ubaida Al-Aani1
1Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha P.O. Box 24144, Qatar.
Cells
|November 27, 2024
概括
早期发现阿尔茨海默氏病 (AD) 是至关重要的. 本综述探讨了脑脊液,血液和唾液等生物流体生物标志物,以及人工智能,以便更容易获得和更精确的AD诊断和治疗.
科学领域:
- 神经学 神经学
- 生物标志物研究 生物标志物研究
- 人工智能在医学中的应用
背景情况:
- 由于有效治疗方法有限,阿尔茨海默病 (AD) 对老龄化人口构成重大挑战.
- 由于AD的快速进展,早期诊断和预防至关重要.
- 目前的AD诊断方法通常是昂贵的和侵入性的,限制了公众的访问.
研究的目的:
- 批判性地研究生物流体生物标志物的功能和作用,以检测AD.
- 专注于大脑脊髓液 (CSF),血液和唾液生物标志物用于AD.
- 探索这些生物标志物在早期检测和成本效益评估方面的潜力.
主要方法:
- 对AD的生物流体生物标志物的现有文献的审查.
- 脑脊液 (CSF),血液和唾液生物标志物的分析.
- 探索人工智能 (AI) 和深度学习 (DL) 在生物标志物解释中的应用.
主要成果:
- 脑脊液生物标志物显示出准确的AD诊断和预后的潜力.
- 血液生物标志物为认知问题的诊断提供了一种最小侵入性,具有成本效益的方法.
- 目前的AD生物标志物缺乏准确性来取代PET扫描和CSF测定,突出需要新型或组合生物标志物.
结论:
- 进一步的研究对于在临床环境中验证AD生物标志物至关重要.
- 将生物标记数据与人工智能工具相结合,显示了个性化AD特征的前景.
- 人工智能和DL可以增强生物标志物分析,以便更准确和及时地诊断AD.
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165


